Chang-Koo Shim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chang-Koo Shim has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Suk-Jae Chung
National Research Laboratory for Transporters Targeted Drug Design, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea
11 shared publicationsDae-Duk Kim
National Research Laboratory for Transporters Targeted Drug Design, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul, South Korea
9 shared publicationsWon-Sik Shim
Gachon University of Medicine and Science, College of Pharmacy, Incheon, South Korea
7 shared publicationsIn-Wha Kim
National Research Laboratory for Transporters Targeted Drug Design, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
5 shared publicationsMin-Koo Choi
Seoul National University
5 shared publicationsSoon-Sun Hong
Inha University School of Medicine
5 shared publications
Latest Publications
- 1 November 2014
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 140, 49-56
Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer
- 1 November 2014
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 140, 49-56
Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer
- 10 January 2012
- Published by Taylor & Francis in Xenobiotica
- Vol. 42 (7) , 603-613
Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters
The phenomenon known as multiple-drug resistance, whereby anti-cancer agents are expelled from cancer cells, makes it necessary to develop methods that will reliably increase the accumulation of anti-cancer agents within cancer cells. To accomplish this goal, a new model compound, Val-SN-38, was synthesized by introducing valine to SN-38, an active ingredient of irinotecan. Val-SN-38 improved intracellular accumulation approximately 5-fold in MCF7 cells, compared with SN-38, and rather than changes in membrane permeability, the amino acid transporter ATB0,+ played a role, whereas the dipeptide transporter PEPT1 did not. Other sodium-dependent amino acid transporters, namely ATA1, ATA2, and ASCT2, were unexpectedly involved in the uptake of Val-SN-38 as well. The efflux of Val-SN-38 by major efflux transporters was variably changed, but not significantly. In summary, the enhanced accumulation of Val-SN-38 in cancer cells was due to augmented uptake via various amino acid transporters. The results of the present study make a compelling argument in favour of a prodrug concept that can improve intracellular accumulation and take advantage of amino acid transporters without significantly inducing multiple-drug resistance.
- 10 January 2012
- Published by Taylor & Francis in Xenobiotica
- Vol. 42 (7) , 603-613
Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters
The phenomenon known as multiple-drug resistance, whereby anti-cancer agents are expelled from cancer cells, makes it necessary to develop methods that will reliably increase the accumulation of anti-cancer agents within cancer cells. To accomplish this goal, a new model compound, Val-SN-38, was synthesized by introducing valine to SN-38, an active ingredient of irinotecan. Val-SN-38 improved intracellular accumulation approximately 5-fold in MCF7 cells, compared with SN-38, and rather than changes in membrane permeability, the amino acid transporter ATB0,+ played a role, whereas the dipeptide transporter PEPT1 did not. Other sodium-dependent amino acid transporters, namely ATA1, ATA2, and ASCT2, were unexpectedly involved in the uptake of Val-SN-38 as well. The efflux of Val-SN-38 by major efflux transporters was variably changed, but not significantly. In summary, the enhanced accumulation of Val-SN-38 in cancer cells was due to augmented uptake via various amino acid transporters. The results of the present study make a compelling argument in favour of a prodrug concept that can improve intracellular accumulation and take advantage of amino acid transporters without significantly inducing multiple-drug resistance.
- 5 October 2011
- Published by Springer Nature in Pharmaceutical Research
- Vol. 29 (3) , 795-805
Liver Cancer Targeting of Doxorubicin with Reduced Distribution to the Heart Using Hematoporphyrin-Modified Albumin Nanoparticles in Rats
To evaluate the usefulness of hematoporphyrin (HP)-modification of the surface of doxorubicin (DOX)-loaded bovine serum albumin (BSA) nanoparticles (NPs) in the liver cancer-selective delivery of DOX. HP-modified NPs (HP-NPs) were prepared by conjugation of amino groups on the surface of NPs with HP, a ligand for low density lipoprotein (LDL) receptors on the hepatoma cells. In vitro cellular accumulation of DOX, in vivo biodistribution of DOX, safety, and anti-tumor efficacy were evaluated for HP-NPs. Cytotoxicity and accumulation of DOX were in the order of HP-NPs>NPs>solution form (SOL). Cellular uptake from HP-NPs was proportional to the expression level of LDL receptors on the cells, indicating possible involvement of LDL receptor-mediated endocytosis (RME) in uptake. The “merit index,” an AUC ratio of DOX in liver (target organ) to DOX in heart (major side effect organ) following iv administration of HP-NPs to hepatoma rats, was 132.5 and 4 times greater compared to SOL and NPs, respectively. The greatest suppression of body weight decrease and tumor size increase was observed for iv-administered HP-NPs in tumor-bearing mice. HP modification appears to be useful in selective delivery of NP-loaded DOX to tumors.
- 5 October 2011
- Published by Springer Nature in Pharmaceutical Research
- Vol. 29 (3) , 795-805
Liver Cancer Targeting of Doxorubicin with Reduced Distribution to the Heart Using Hematoporphyrin-Modified Albumin Nanoparticles in Rats
To evaluate the usefulness of hematoporphyrin (HP)-modification of the surface of doxorubicin (DOX)-loaded bovine serum albumin (BSA) nanoparticles (NPs) in the liver cancer-selective delivery of DOX. HP-modified NPs (HP-NPs) were prepared by conjugation of amino groups on the surface of NPs with HP, a ligand for low density lipoprotein (LDL) receptors on the hepatoma cells. In vitro cellular accumulation of DOX, in vivo biodistribution of DOX, safety, and anti-tumor efficacy were evaluated for HP-NPs. Cytotoxicity and accumulation of DOX were in the order of HP-NPs>NPs>solution form (SOL). Cellular uptake from HP-NPs was proportional to the expression level of LDL receptors on the cells, indicating possible involvement of LDL receptor-mediated endocytosis (RME) in uptake. The “merit index,” an AUC ratio of DOX in liver (target organ) to DOX in heart (major side effect organ) following iv administration of HP-NPs to hepatoma rats, was 132.5 and 4 times greater compared to SOL and NPs, respectively. The greatest suppression of body weight decrease and tumor size increase was observed for iv-administered HP-NPs in tumor-bearing mice. HP modification appears to be useful in selective delivery of NP-loaded DOX to tumors.
- 13 September 2010
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry
- Vol. 20 (41) , 9042-9046
99mTc-hematoporphyrin linked albumin nanoparticles for lung cancer targeted photodynamic therapy and imaging
In this study, we fabricated albumin nanoparticles (ANP) using a solvent diffusion method and modified the surface of the ANP with hematoporphyrin (HP) which has been used for cancer photodynamic therapy. Hematoporphyrin linked albumin nanoparticles (HP-ANP) were further functionalized with gamma-emitting nuclides ( 99mTc) for scintigraphic imaging. The fabrication method for HP-ANP was optimized extensively to obtain HP-ANP particles within the size range of 100 to 200 nm. HP-ANP had enhanced accumulation in A549 and CT-26 cancer cell lines, and photodynamic activity against A549 cells after UV exposure. HP-ANP also showed increased accumulation in murine lung tumors, which was induced by CT-26 colon cancer cells, compared to normal lungs. Pharmacokinetics of 99mTc chelated HP-ANP ( 99mTc-HP-ANP) was estimated through scintigraphic imaging of rabbits. 99mTc-HP-ANP demonstrated good imaging properties in the rabbit with a much more extended biological half life compared to 99mTc-HP. 99mTc-HP-ANP could be utilized as a radio-diagnostic tool for cancer as well as the obvious application for photodynamic therapy.
- 13 September 2010
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry
- Vol. 20 (41) , 9042-9046
99mTc-hematoporphyrin linked albumin nanoparticles for lung cancer targeted photodynamic therapy and imaging
In this study, we fabricated albumin nanoparticles (ANP) using a solvent diffusion method and modified the surface of the ANP with hematoporphyrin (HP) which has been used for cancer photodynamic therapy. Hematoporphyrin linked albumin nanoparticles (HP-ANP) were further functionalized with gamma-emitting nuclides ( 99mTc) for scintigraphic imaging. The fabrication method for HP-ANP was optimized extensively to obtain HP-ANP particles within the size range of 100 to 200 nm. HP-ANP had enhanced accumulation in A549 and CT-26 cancer cell lines, and photodynamic activity against A549 cells after UV exposure. HP-ANP also showed increased accumulation in murine lung tumors, which was induced by CT-26 colon cancer cells, compared to normal lungs. Pharmacokinetics of 99mTc chelated HP-ANP ( 99mTc-HP-ANP) was estimated through scintigraphic imaging of rabbits. 99mTc-HP-ANP demonstrated good imaging properties in the rabbit with a much more extended biological half life compared to 99mTc-HP. 99mTc-HP-ANP could be utilized as a radio-diagnostic tool for cancer as well as the obvious application for photodynamic therapy.
- 10 March 2010
- Published by Springer Nature in Pharmaceutical Research
- Vol. 27 (5) , 823-831
Increased Affinity to Canalicular P-gp via Formation of Lipophilic Ion-Pair Complexes with Endogenous Bile Salts is Associated with Mw Threshold in Hepatobiliary Excretion of Quaternary Ammonium Compounds
We intended to elucidate the mechanism of the molecular weight (Mw) threshold (i.e., 200 ± 50) for appreciable hepatobiliary excretion of quaternary ammonium compounds (QACs) in rats. We measured the effect of ion-pair complexation of QACs with taurodeoxycholate (TDC), an endogenous anionic bile salt, on the apparent partition coefficients (APC) of QACs between n-octanol and phosphate buffer, and the inhibition of organic cation transporter1 (OCT1)- and P-glycoprotein (P-gp)-mediated transport of representative substrates. By measuring the APC, we demonstrated that there is a Mw threshold of 200 ± 50 in the ion-pair complexation of QACs with an endogenous bile salt, TDC. We also demonstrated, by measuring the inhibition of relevant transports, that a Mw threshold of 200 ± 50 exists for the binding of QACs to canalicular P-gp, but not for sinusoidal OCT1. The Mw threshold values for ion-pair formation and P-gp binding were identical and consistent with the reported Mw threshold value for appreciable biliary excretion of QACs in rats. Mw-dependent binding of QACs to canalicular P-gp contributes in part to the mechanism of the Mw threshold of 200 ± 50. The formation of lipophilic ion-pair complexes with bile salts, followed by stronger binding to canalicular P-gp, appears to accelerate biliary excretion of QACs with a high Mw.
- 10 March 2010
- Published by Springer Nature in Pharmaceutical Research
- Vol. 27 (5) , 823-831
Increased Affinity to Canalicular P-gp via Formation of Lipophilic Ion-Pair Complexes with Endogenous Bile Salts is Associated with Mw Threshold in Hepatobiliary Excretion of Quaternary Ammonium Compounds
We intended to elucidate the mechanism of the molecular weight (Mw) threshold (i.e., 200 ± 50) for appreciable hepatobiliary excretion of quaternary ammonium compounds (QACs) in rats. We measured the effect of ion-pair complexation of QACs with taurodeoxycholate (TDC), an endogenous anionic bile salt, on the apparent partition coefficients (APC) of QACs between n-octanol and phosphate buffer, and the inhibition of organic cation transporter1 (OCT1)- and P-glycoprotein (P-gp)-mediated transport of representative substrates. By measuring the APC, we demonstrated that there is a Mw threshold of 200 ± 50 in the ion-pair complexation of QACs with an endogenous bile salt, TDC. We also demonstrated, by measuring the inhibition of relevant transports, that a Mw threshold of 200 ± 50 exists for the binding of QACs to canalicular P-gp, but not for sinusoidal OCT1. The Mw threshold values for ion-pair formation and P-gp binding were identical and consistent with the reported Mw threshold value for appreciable biliary excretion of QACs in rats. Mw-dependent binding of QACs to canalicular P-gp contributes in part to the mechanism of the Mw threshold of 200 ± 50. The formation of lipophilic ion-pair complexes with bile salts, followed by stronger binding to canalicular P-gp, appears to accelerate biliary excretion of QACs with a high Mw.
- 1 November 2009
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 126 (2) , 294-299
Long-term administration of an aqueous extract of dried, immature fruit of Poncirus trifoliata (L.) Raf. suppresses body weight gain in rats
- 1 November 2009
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 126 (2) , 294-299
Long-term administration of an aqueous extract of dried, immature fruit of Poncirus trifoliata (L.) Raf. suppresses body weight gain in rats
- 11 September 2009
- Published by Springer Nature in Pharmaceutical Research
- Vol. 26 (11) , 2504-2512
Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats
To develop an improved sustained-release (SR) formulation of exenatide (a therapy for patients with type 2 diabetes mellitus) in a biweekly dosage form with therapeutic efficacy comparable to that achieved with twice-daily injections of the drug. A SR formulation of exenatide, DA-3091, was prepared by single-emulsion solvent evaporation using poly(D,L-lactide-co-glycolide). Plasma exenatide, as well as plasma insulin, non-fasting blood glucose and HbA1c concentrations, and changes in food intake and body weight were evaluated in both Zucker diabetic fatty (ZDF) and ZDF lean control rats. After a single SC administration of DA-3091 (i.e., 2 mg/kg of exenatide), the plasma exenatide concentration increased and remained elevated in both groups. The concentrations of non-fasting blood glucose and HbA1c decreased significantly following a single SC injection of DA-3091 only in ZDF rats, indicating that the effects of exenatide are dependent on blood glucose concentration. On the other hand, both food intake and body weight gain were reduced in ZDF and ZDF lean control rats. A single injection of DA-3091 (i.e., 2 mg/kg of exenatide) lowered non-fasting blood glucose and HbA1c concentrations more effectively than 14 days of twice-daily administration of exenatide (i.e., 1.96 mg/kg of exenatide). DA-3091 has the potential to be used safely and efficaciously in a biweekly dosing regimen.
- 11 September 2009
- Published by Springer Nature in Pharmaceutical Research
- Vol. 26 (11) , 2504-2512
Pharmacokinetics and Efficacy of a Biweekly Dosage Formulation of Exenatide in Zucker Diabetic Fatty (ZDF) Rats
To develop an improved sustained-release (SR) formulation of exenatide (a therapy for patients with type 2 diabetes mellitus) in a biweekly dosage form with therapeutic efficacy comparable to that achieved with twice-daily injections of the drug. A SR formulation of exenatide, DA-3091, was prepared by single-emulsion solvent evaporation using poly(D,L-lactide-co-glycolide). Plasma exenatide, as well as plasma insulin, non-fasting blood glucose and HbA1c concentrations, and changes in food intake and body weight were evaluated in both Zucker diabetic fatty (ZDF) and ZDF lean control rats. After a single SC administration of DA-3091 (i.e., 2 mg/kg of exenatide), the plasma exenatide concentration increased and remained elevated in both groups. The concentrations of non-fasting blood glucose and HbA1c decreased significantly following a single SC injection of DA-3091 only in ZDF rats, indicating that the effects of exenatide are dependent on blood glucose concentration. On the other hand, both food intake and body weight gain were reduced in ZDF and ZDF lean control rats. A single injection of DA-3091 (i.e., 2 mg/kg of exenatide) lowered non-fasting blood glucose and HbA1c concentrations more effectively than 14 days of twice-daily administration of exenatide (i.e., 1.96 mg/kg of exenatide). DA-3091 has the potential to be used safely and efficaciously in a biweekly dosing regimen.
- 24 June 2009
- Published by Taylor & Francis in Xenobiotica
- Vol. 39 (10) , 711-721
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp
(2009). Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp. Xenobiotica: Vol. 39, No. 10, pp. 711-721.
- 24 June 2009
- Published by Taylor & Francis in Xenobiotica
- Vol. 39 (10) , 711-721
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp
(2009). Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp. Xenobiotica: Vol. 39, No. 10, pp. 711-721.
- 24 June 2009
- Published by Taylor & Francis in Xenobiotica
- Vol. 39 (10) , 738-748
Tissue-specific changes in mRNA expression of Abc and Slc transporters in murine pulmonary tuberculosis
A pulmonary tuberculosis mouse model was used to assess the pharmacodynamic and pharmacokinetic characteristics of tuberculosis therapeutics. While membrane transporters play important roles in drug disposition and physiological homeostasis, their expressional changes and contribution have never been analysed in a tuberculosis animal model. The mRNA expression level of 20 Abc family transporters and 32 Slc family transporters in tuberculosis-infected mice were compared with those in naïve uninfected mice using real-time polymerase chain reaction (PCR). Mycobacterium tuberculosis infection induced many dramatic expression changes of families of both Abc transporters and Slc transporters at 4 and 8 weeks, as observed in the livers, kidneys, and intestines of test mice — and in a different mode, in the lungs and spleens as well. These changes were dependent on the tuberculosis progression with the tissue-specific manner, that is, in the lungs, the number of transporters of which the expression level changed due to M. tuberculosis infection had increased, and the magnitude of change also greater at 8 weeks, while in the spleen, the transcription of most transporters except Mrps had not changed or had recovered back to the same level of naïve transcription at 8 weeks. Understanding the expression changes of transporters will assist in setting up rational preclinical dosing plans through the ability to predict the pharmacokinetics of new anti-tuberculosis chemotherapeutics and, furthermore, will assist in the design of safer and more efficient drug regimens.
- 24 June 2009
- Published by Taylor & Francis in Xenobiotica
- Vol. 39 (10) , 738-748
Tissue-specific changes in mRNA expression of Abc and Slc transporters in murine pulmonary tuberculosis
A pulmonary tuberculosis mouse model was used to assess the pharmacodynamic and pharmacokinetic characteristics of tuberculosis therapeutics. While membrane transporters play important roles in drug disposition and physiological homeostasis, their expressional changes and contribution have never been analysed in a tuberculosis animal model. The mRNA expression level of 20 Abc family transporters and 32 Slc family transporters in tuberculosis-infected mice were compared with those in naïve uninfected mice using real-time polymerase chain reaction (PCR). Mycobacterium tuberculosis infection induced many dramatic expression changes of families of both Abc transporters and Slc transporters at 4 and 8 weeks, as observed in the livers, kidneys, and intestines of test mice — and in a different mode, in the lungs and spleens as well. These changes were dependent on the tuberculosis progression with the tissue-specific manner, that is, in the lungs, the number of transporters of which the expression level changed due to M. tuberculosis infection had increased, and the magnitude of change also greater at 8 weeks, while in the spleen, the transcription of most transporters except Mrps had not changed or had recovered back to the same level of naïve transcription at 8 weeks. Understanding the expression changes of transporters will assist in setting up rational preclinical dosing plans through the ability to predict the pharmacokinetics of new anti-tuberculosis chemotherapeutics and, furthermore, will assist in the design of safer and more efficient drug regimens.
- 1 March 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (3) , 970-984
Lung-Specific Delivery of Paclitaxel by Chitosan-Modified PLGA Nanoparticles Via Transient Formation of Microaggregates
- 1 March 2009
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 98 (3) , 970-984
Lung-Specific Delivery of Paclitaxel by Chitosan-Modified PLGA Nanoparticles Via Transient Formation of Microaggregates